Fig. 6.

Delayed treatment with NM922 reduces myofibroblast abundance in vivo. A and B: representative ×20 fluorescent images of slides costained for α-smooth muscle actin (α-SMA; red), von Willebrand factor (VWF; green), and DAPI (blue). Arrows denote αSMA⁺/VWF⁻ cells. C: αSMA⁺/VWF⁻ cell counts at 16 wk after TAC for mice treated with NM922 or vehicle. D–F: protein expression of α-SMA (D), cyclooxygenase-2 (COX-2; E), and transforming growth factor-β (TGF-β; F). GAPDH was used as a loading control. Numbers inside bars denote numbers of animals/group. RU, relative units; NS, not significant.